Cited by 24Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismImmunotherapy and Immune Responses

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

Open access
van Duijn, Anneloes, Willemsen, Karin J., van Uden, Nathalie O. P., Hoyng, Lieke, Erades, Sterre, Koster, Jan, Luiten, Rosalie M., Bakker, Walbert J.·2022·Cancer Immunology, Immunotherapy

Abstract

Cancer cells are able to escape immune surveillance by upregulating programmed death ligand 1 (PD-L1). A key regulator of PD-L1 expression is transcriptional stimulation by the IFNγ/JAK/STAT pathway. Recent studies suggest that hypoxia can induce PD-L1 expression. As hypoxia presents a hallmark of solid tumor development, hypoxic control of PD-L1 expression may affect the efficacy of cancer immunotherapy. This study aims to explore the hypoxic regulation of PD-L1 expression in human melanoma, and its interaction with IFNγ-induced PD-L1 expression. Analysis of the cutaneous melanoma dataset from the cancer genome atlas revealed a significant correlation of the HIF1-signaling geneset signature with PD-L1 mRNA expression. However, this correlation is less pronounced than other key pathways known to control PD-L1 expression, including the IFNγ/JAK/STAT pathway. This secondary role of HIF1 in PD-L1 regulation was confirmed by analyzing single-cell RNA-sequencing data of 33 human melanoma tissues. Interestingly, PD-L1 expression in these melanoma tissues was primarily found in macrophages. However, also in these cells STAT1, and not HIF1, displayed the most pronounced correlation with PD-L1 expression. Moreover, we observed that hypoxia differentially affects PD-L1 expression in human melanoma cell lines. Knockdown of HIF1 expression indicated a minor role for HIF1 in regulating PD-L1 expression. A more pronounced influence of hypoxia was found on IFNγ-induced PD-L1 mRNA expression, which is controlled at a 952 bp PD-L1 promoter fragment. These findings, showing the influence of hypoxia on IFNγ-induced PD-L1 expression, are relevant for immunotherapy, as both IFNγ and hypoxia are frequently present in the tumor microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-021-03007-1

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Analysis of the melanoma genome atlas data shows a correlation of the HIF-1 signaling signature with PD-L1 mRNA expression, especially with IFN-γ-induced expression of PD-L1 mRNA.

    “For instance, analysis of the melanoma genome atlas data shows a correlation of the HIF-1 signaling signature with PD-L1 mRNA expression, especially with IFN-γ–induced expression of PD-L1 mRNA (25).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 37 · Cited by 24

Authors
van Duijn, A., Willemsen, K. J., van Uden, N. O. P., Hoyng, L., Erades, S., Koster, J., Luiten, R. M., & Bakker, W. J.
Affiliations
Amsterdam University Medical Centers (NL)
Corresponding author
Bakker, Walbert J.
Venue
Cancer Immunology, Immunotherapy
Published
2021-07-15
Volume
71
Issue
3
Pages
529-540
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3179417869
Cited by
24
References
37
Citations by year
2026: 4 · 2025: 5 · 2024: 3 · 2023: 8 · 2022: 4
FWCI
1.36
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Immunotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
PD-L1 expression, hypoxia, HIF-1, melanoma, interferon-gamma, JAK/STAT signaling, STAT1, tumor microenvironment, macrophages, cancer immunotherapy, immune evasion
MeSH terms
Tumor-Associated Macrophages, Animals, Hypoxia, Humans, Interferon-gamma, Melanoma, Melanoma, Experimental, Signal Transduction, Gene Expression Regulation, Neoplastic, RNA, Small Interfering, Cell Line, Tumor, Mice, Hypoxia-Inducible Factor 1, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review